GDF15, a Cardioprotective TGF-β Superfamily Protein
2006; Lippincott Williams & Wilkins; Volume: 98; Issue: 3 Linguagem: Inglês
10.1161/01.res.0000207919.83894.9d
ISSN1524-4571
AutoresTetsuro Ago, Junichi Sadoshima,
Tópico(s)Macrophage Migration Inhibitory Factor
ResumoHomeCirculation ResearchVol. 98, No. 3GDF15, a Cardioprotective TGF-β Superfamily Protein Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBGDF15, a Cardioprotective TGF-β Superfamily Protein Tetsuro Ago and Junichi Sadoshima Tetsuro AgoTetsuro Ago From the Cardiovascular Research Institute, Department of Cell Biology and Molecular Medicine, UMDNJ, New Jersey Medical School, Newark. and Junichi SadoshimaJunichi Sadoshima From the Cardiovascular Research Institute, Department of Cell Biology and Molecular Medicine, UMDNJ, New Jersey Medical School, Newark. Originally published17 Feb 2006https://doi.org/10.1161/01.RES.0000207919.83894.9dCirculation Research. 2006;98:294–297The transforming growth factor-β (TGF-β) superfamily proteins, comprising more than 40 members (broadly divided into the TGF-βs/activins/nodal family and the bone morphogenetic proteins [BMPs]/Müllerrian inhibiting substance/growth and differentiation factors [GDFs] family), were originally identified as molecules important for regulating development, differentiation, and tissue repair in various organs.1 TGF-β1, a founding member of the TGF-β superfamily, plays a key role in mediating cardiac hypertrophy2 and remodeling after myocardial infarction (MI) as an autocrine/paracrine factor.3 Increased TGF-β1 expression is considered one of the few molecular markers that potentially discriminate between compensated and decompensated cardiac hypertrophy.3 Although TGF-β1 may function protectively after MI by promoting scar formation, inhibiting neutrophil infiltration, and facilitating cardiomyogenic differentiation of adult hematopoietic stem cells,4 such beneficial effects last only briefly and sustained activation of TGF-β1 causes structural remodeling, eventually leading to cardiac failure.5 Thus, TGF-β1 is generally regarded as detrimental, inducing cardiac hypertrophy and failure in the adult heart.Compared with the wealth of knowledge regarding the effects of TGF-β1 on the heart, much less is known as to how other members of the TGF-β superfamily affect cardiac hypertrophy and failure.6 In this issue of Circulation Research, two companion articles report the effect of growth and differentiation factor 15 (GDF15), a 12-kDa secreted protein (and a 25-kDa disulfide-linked dimer) belonging to the TGF-β superfamily, on cardiac hypertrophy and apoptosis.7,8 GDF15 is highly expressed in the placenta and the prostate, but not normally in many other organs, including the heart.9,10 However, expression of GDF15 is induced rapidly by IL-1, TNFα, and TGF-β in macrophages, thereby limiting macrophage activation and inflammation (Figure 1).9 In addition, p53, a tumor suppressor protein, induces expression of GDF15, which acts as a growth inhibitory molecule in tumor cells (Figure 1).10 Such growth inhibitory actions of GDF15 are unique compared with those of other targets of p53, such as p21/Waf-1, because GDF15 can act on neighboring cells as an "extracellular" messenger after being secreted. Kemph et al found that expression of GDF15 is induced rapidly in cardiomyocytes on ischemia/reperfusion (I/R) via the nitric oxide-peroxynitrite-dependent signaling pathway.8 GDF15 is also upregulated by other cardiovascular events triggering oxidative stress, including pressure overload, heart failure,7 and atherosclerosis11 (Figure 1). Download figureDownload PowerPointFigure 1. Known upstream stimulators and functions of GDF15In the heart, Gdf15 gene targeted mice exhibited greater hypertrophy, which could also be attributable to exaggerated hyperplasia, with reduced left ventricular function in response to pressure-overload,7 and a greater MI and apoptosis after I/R.8 This is in striking contrast with Tgfb1 gene targeted mice, in which angiotensin II–induced hypertrophy is abrogated.2 Conversely, heart-specific GDF15-overexpressing mice are resistant to pressure overload-induced hypertrophy.7 These results are consistent with the notion that GDF15 is a protective molecule for the heart. This leads to the question as to why GDF15 exerts cardioprotective effects whereas TGF-β1 does the opposite, despite the fact that both activate similar downstream signaling pathways, including the Smad (Small mother against decapentaplegic)-dependent signaling pathway.TGF-β family proteins bind to distinct type I and type II serine/threonine kinase receptors. The specificity of the intracellular signaling is mainly determined by type I receptors (ALK1 to ALK7). Intracellular signaling mechanisms induced by the TGF-β superfamily are broadly divided into Smad-dependent and -independent pathways (Figure 2).12 Receptor-activated Smads, including Smad2/3 and Smad1/5/8, are phosphorylated by type I receptors and, after forming a heterotrimeric complex with the common mediator Smad, namely Smad4, they are translocated into the nucleus and modulate transcription. The molecules activated by the Smad-independent pathway include MAPKs, TAK-1, and PI3K/Akt, although the precise mechanisms by which TGF-β receptors activate these molecules are not clearly understood.12Download figureDownload PowerPointFigure 2. Intracellular signaling pathways of TGF-β superfamily members and their cardiac effects. Bold lines indicate putative GDF15-activated pathways. Note that some Smads may mediate hypertrophy and apoptosis in the presence of additional signaling mechanisms and transcription factors.Is the Smad-Dependent Pathway Good or Bad for the Heart?Because the Smad-dependent pathway, the canonical TGF-β signaling mechanism, is activated under several pathological conditions in the heart,13 it was postulated that the Smad-dependent pathway mediates detrimental functions of TGF-β1. However, recent studies showed that this hypothesis may not necessarily be true. Wang et al reported a surprising observation that cardiac-specific Smad4 knockout mice resulted in cardiac hypertrophy and heart failure.14 Because Smad4 is considered the common transcriptional mediator of the Smad-dependent pathway, the observation by Wang et al suggests that the Smad-dependent pathway rather inhibits cardiac hypertrophy, apoptosis, and fibrosis, thereby acting in a protective manner. Although this observation does not exclude the participation of active Smads in hypertrophy and failure, the disadvantage caused by the lack of Smad4 overwhelms the few, if any, advantages to abolishing active Smad signaling in the heart. Xu et al found that Smad2 and Smad3 are phosphorylated on GDF15 treatment in cultured cardiomyocytes.7 Furthermore, adenovirus-mediated Smad2 overexpression suppressed hypertrophic responses, mimicking the effect of GDF15 overexpression.7 Together with the finding that GDF15 and Smad2 failed to show additive effects,7 these results strongly suggest that Smad2/3 mediate antihypertrophic and other cardioprotective effects of GDF15. Masaki et al reported that Smad1 is activated by I/R, which in turn reduces the size of MI and the amount of apoptotic cell death through upregulation of Bcl-xL and β-catenin.15 Moreover, the loss of Smad5 also results in increased apoptosis in cardiomyocytes.16 Taken together, the Smad-dependent pathway appears to play antihypertrophic and antiapoptotic roles, thereby mediating the protective effect of GDF15 while counteracting the detrimental aspect of TGF-β1 in the heart.Besides GDF15, BMP-2 seems to have an antiapoptotic effect through activation of Smad1.6 However, the protective effects for the heart in vivo caused by BMP-2 remain to be shown. Thus, to our knowledge, GDF15 is the first TGF-β superfamily protein that plays a cardioprotective role in vivo in the adult heart. Because GDF15 activates Smad2 and Smad3,7 ALK-4/5/7 could be the candidate receptors for GDF15. Alternatively, judging from the similarity in the primary structure and Smads activation, GDF15 may be closer to the BMP subfamily than to the TGF-β subfamily.1 Because BMP-2 activates ALK-2/3/6, which in turn phosphorylate Smad1/5, GDF15 may also activate one of these type I receptors and Smad1/Smad5 as well.What, then, is the signaling mechanism mediating the detrimental effects of the TGF-β family? Among the various signaling mechanisms activated by TGF-β1, the role of TAK-1 in mediating pathologic hypertrophy seems best established. TAK-1 is rapidly activated by TGF-β1, and overexpression of TAK-1 in the heart causes cardiac hypertrophy and failure.17 Alternatively, the Smad-dependent mechanism may cooperatively mediate pathological hypertrophy in the presence of TAK-1 activation.13 In any case, it is possible that the Smad-independent pathway may determine whether each member of the TGF-β superfamily mediates protective or detrimental functions in the adult heart. Interestingly, both ERKs and Akt, protective molecules for the heart, are activated by GDF15. In this regard, it would be interesting to confirm that TAK-1/p38 MAPK signaling is not actually activated by GDF15 in cardiomyocytes.PerspectivesIn summary, the studies reported by Xu et al7 and Kemph et al8 indicate that GDF15 is a promising cardioprotective agent against heart failure and I/R. A cautionary note is that GDF15 induces apoptosis in some cancer cells.18 Thus, the function of GDF15 may depend on the availability of type I and II receptors and/or Smads and concomitant activation of Smad-independent signaling mechanisms. Identifying the receptor subtype, the underlying signaling mechanism, and further downstream targets of GDF15 should be useful for further elucidation of the cardioprotective mechanism in various pathological conditions. It is advisable that the long-term protective effects of GDF15 overexpression on cardiac function after MI should be confirmed using GDF15 overexpression mice. Recently, several diffusible molecules, whose expression is strongly upregulated by cardiac stresses, have been identified as powerful cardioprotective factors.19,20 Because multicellular organisms are known to acquire "stress resistance" through stress-induced upregulation of diffusible factors which not only protect the cells under stress but also alert surrounding cells to prepare for coming disasters, identifying such molecules through expression profile analyses will continue to be a fruitful approach for future drug discovery.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.We thank Dr Stephen F. Vatner and Daniela Zablocki for critical reading of the manuscript.FootnotesCorrespondence to Junichi Sadoshima, Cardiovascular Research Institute, Department of Cell Biology and Molecular Medicine, UMDNJ, New Jersey Medical School, 185 South Orange Avenue, MSB G-609, Newark, NJ 07103. E-mail [email protected] References 1 Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003; 113: 685–700.CrossrefMedlineGoogle Scholar2 Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, Kimball TR, Doetschman T. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest. 2002; 109: 787–796.CrossrefMedlineGoogle Scholar3 Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999; 79: 215–262.CrossrefMedlineGoogle Scholar4 Li TS, Hayashi M, Ito H, Furutani A, Murata T, Matsuzaki M, Hamano K. Regeneration of infarcted myocardium by intramyocardial implantation of ex vivo transforming growth factor-beta-preprogrammed bone marrow stem cells. Circulation. 2005; 111: 2438–2445.LinkGoogle Scholar5 Ikeuchi M, Tsutsui H, Shiomi T, Matsusaka H, Matsushima S, Wen J, Kubota T, Takeshita A. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res. 2004; 64: 526–535.CrossrefMedlineGoogle Scholar6 Izumi M, Fujio Y, Kunisada K, Negoro S, Tone E, Funamoto M, Osugi T, Oshima Y, Nakaoka Y, Kishimoto T, Yamauchi-Takihara K, Hirota H. Bone morphogenetic protein-2 inhibits serum deprivation-induced apoptosis of neonatal cardiac myocytes through activation of the Smad1 pathway. J Biol Chem. 2001; 276: 31133–31141.CrossrefMedlineGoogle Scholar7 Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, Hewett TE, Breit SN, Molkentin JD. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res. 2006; 98: 342–350.LinkGoogle Scholar8 Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin JD, Niessen HW, Drexler H, Wollert KC. Transforming growth factor-{beta} superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res. 2006; 98: 351–360.LinkGoogle Scholar9 Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A. 1997; 94: 11514–11519.CrossrefMedlineGoogle Scholar10 Tan M, Wang Y, Guan K, Sun Y. PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci U S A. 2000; 97: 109–114.CrossrefMedlineGoogle Scholar11 Brown DA, Breit SN, Buring J, Fairlie WD, Bauskin AR, Liu T, Ridker PM. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet. 2002; 359: 2159–2163.CrossrefMedlineGoogle Scholar12 Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425: 577–584.CrossrefMedlineGoogle Scholar13 Euler-Taimor G, Heger J. The complex pattern of SMAD signaling in the cardiovascular system. Cardiovasc Res. 2006; 69: 15–25.CrossrefMedlineGoogle Scholar14 Wang J, Xu N, Feng X, Hou N, Zhang J, Cheng X, Chen Y, Zhang Y, Yang X. Targeted disruption of Smad4 in cardiomyocytes results in cardiac hypertrophy and heart failure. Circ Res. 2005; 97: 821–828.LinkGoogle Scholar15 Masaki M, Izumi M, Oshima Y, Nakaoka Y, Kuroda T, Kimura R, Sugiyama S, Terai K, Kitakaze M, Yamauchi-Takihara K, Kawase I, Hirota H. Smad1 protects cardiomyocytes from ischemia-reperfusion injury. Circulation. 2005; 111: 2752–2759.LinkGoogle Scholar16 Sun Y, Zhou J, Liao X, Lu Y, Deng C, Huang P, Chen Q, Yang X. Disruption of Smad5 gene induces mitochondria-dependent apoptosis in cardiomyocytes. Exp Cell Res. 2005; 306: 85–93.CrossrefMedlineGoogle Scholar17 Zhang D, Gaussin V, Taffet GE, Belaguli NS, Yamada M, Schwartz RJ, Michael LH, Overbeek PA, Schneider MD. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med. 2000; 6: 556–563.CrossrefMedlineGoogle Scholar18 Liu T, Bauskin AR, Zaunders J, Brown DA, Pankhurst S, Russell PJ, Breit SN. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res. 2003; 63: 5034–5040.MedlineGoogle Scholar19 McGrath MF, Kuroski de Bold ML, de Bold AJ. The endocrine function of the heart. Trends Endocrinol Metab. 2005; 16: 469–477.CrossrefMedlineGoogle Scholar20 Tao L, Gao E, Bryan NS, Qu Y, Liu HR, Hu A, Christopher TA, Lopez BL, Yodoi J, Koch WJ, Feelisch M, Ma XL. Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: role of S-nitrosation. Proc Natl Acad Sci U S A. 2004; 101: 11471–11476.CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By He Y, Zhang X, Zhang Y, Luo W, Zhu Z, Song K and Shi J (2022) Growth differentiation factor 15 is required for triple-negative breast cancer cell growth and chemoresistance, Anti-Cancer Drugs, 10.1097/CAD.0000000000001434, 34:3, (351-360), Online publication date: 1-Mar-2023. van Santen V, Zandieh Doulabi B, Semeins C, Hogervorst J, Bratengeier C and Bakker A (2023) Compressed Prostate Cancer Cells Decrease Osteoclast Activity While Enhancing Osteoblast Activity In Vitro, International Journal of Molecular Sciences, 10.3390/ijms24010759, 24:1, (759) Poppenberg K, Chien A, Santo B, Chaves L, Veeturi S, Waqas M, Monteiro A, Dmytriw A, Burkhardt J, Mokin M, Snyder K, Siddiqui A and Tutino V (2022) Profiling of Circulating Gene Expression Reveals Molecular Signatures Associated with Intracranial Aneurysm Rupture Risk, Molecular Diagnosis & Therapy, 10.1007/s40291-022-00626-x, 27:1, (115-127), Online publication date: 1-Jan-2023. Galassi A, Ciceri P, Bono V, Magagnoli L, Sala M, Artioli L, Rovito R, Hadla M, Yellenki V, D'Arminio Monforte A, Tincati C, Cozzolino M and Marchetti G (2022) Growth Differentiation Factor 15 (GDF-15) Levels Associate with Lower Survival in Chronic Kidney Disease Patients with COVID-19, Biomedicines, 10.3390/biomedicines10123251, 10:12, (3251) Mei Y, Zhao Z, Lyu Y and Li Y (2022) Circulating growth differentiation factor 15 levels and apolipoprotein B to apolipoprotein A1 ratio in coronary artery disease patients with type 2 diabetes mellitus, Lipids in Health and Disease, 10.1186/s12944-022-01667-1, 21:1, Online publication date: 1-Dec-2022. Hou C, Tsui K, Chang K, Sung H, Hsu S, Lin Y, Yang P, Chen C, Feng T and Juang H (2022) Caffeic acid phenethyl ester inhibits the growth of bladder carcinoma cells by upregulating growth differentiation factor 15, Biomedical Journal, 10.1016/j.bj.2021.10.006, 45:5, (763-775), Online publication date: 1-Oct-2022. Chen M, Ding N, Mok Y, Mathews L, Hoogeveen R, Ballantyne C, Chen L, Coresh J and Matsushita K (2022) Growth Differentiation Factor 15 and the Subsequent Risk of Atrial Fibrillation: The Atherosclerosis Risk in Communities Study, Clinical Chemistry, 10.1093/clinchem/hvac096, 68:8, (1084-1093), Online publication date: 27-Jul-2022. Alyami R and Alhowikan A Effect of supervised exercise training on exercise capacity, pulmonary function and growth differentiation factor 15 levels in patients with interstitial lung disease: A preliminary study, Isokinetics and Exercise Science, 10.3233/IES-210123, 30:3, (221-229) Lewis G, Rosala‐Hallas A, Dodd S, Schelbert E, Williams S, Cunnington C, McDonagh T and Miller C (2022) Characteristics Associated With Growth Differentiation Factor 15 in Heart Failure With Preserved Ejection Fraction and the Impact of Pirfenidone, Journal of the American Heart Association, 11:14, Online publication date: 19-Jul-2022. Hou C, Tsui K, Chen S, Chang K, Sung H, Hsu S, Lin Y, Feng T and Juang H (2022) The Upregulation of Caffeic Acid Phenethyl Ester on Growth Differentiation Factor 15 Inhibits Transforming Growth Factor β/Smad Signaling in Bladder Carcinoma Cells, Biomedicines, 10.3390/biomedicines10071625, 10:7, (1625) Lidgard B, Zelnickv L, Anderson A, Feldman H, Go A, He J, Kansal M, Mohanty M, Mehta R, Shlipak M, Soliman E, Weir M and Bansal N (2022) Cardiac Biomarkers and Risk of Atherosclerotic Cardiovascular Disease in Patients with CKD, Kidney360, 10.34067/KID.0006222021, 3:5, (859-871), Online publication date: 26-May-2022. Jiao Y, Huang Z, Chen M, Zhou X, Lu H, Wang B and Dai X (2022) A label-free amperometric immunosensor with improved electrocatalytic 3D braided AuPtCu-SWCNTs@MoS 2 -rGO for human growth differentiation factor-15 detection , Analytical Methods, 10.1039/D1AY02198B, 14:14, (1420-1429) Yamaguchi H, Nishiyama M, Tomioka K, Hongo H, Tokumoto S, Ishida Y, Toyoshima D, Kurosawa H, Nozu K, Maruyama A, Tanaka R and Nagase H (2022) Growth and differentiation factor-15 as a potential prognostic biomarker for status-epilepticus-associated-with-fever: A pilot study, Brain and Development, 10.1016/j.braindev.2021.10.003, 44:3, (210-220), Online publication date: 1-Mar-2022. Hacıoğlu Y, Kılıçkaya P, Rakıcı İ, Karataş S, Pişkinpaşa M and Karabağ T (2022) Correlation of Coronary Calcium Scores with Growth Differentiation Factor-15 Levels in Patients with Coronary Artery Disease, Istanbul Medical Journal, 10.4274/imj.galenos.2022.58740, 23:1, (74-78), Online publication date: 1-Feb-2022. Smirne C, Croce E, Di Benedetto D, Cantaluppi V, Comi C, Sainaghi P, Minisini R, Grossini E and Pirisi M (2022) Oxidative Stress in Non-Alcoholic Fatty Liver Disease, Livers, 10.3390/livers2010003, 2:1, (30-76) Mun K and Hinman J (2022) Inflammation and the Link to Vascular Brain Health: Timing Is Brain, Stroke, 53:2, (427-436), Online publication date: 1-Feb-2022. Wang D, Wei X, Geng X, Li P and Li L (2022) GDF15 enhances proliferation of aged chondrocytes by phosphorylating SMAD2, Journal of Orthopaedic Science, 10.1016/j.jos.2020.12.004, 27:1, (249-256), Online publication date: 1-Jan-2022. Lassus J, Tarvasmäki T and Tolppanen H (2022) Biomarkers in cardiogenic shock , 10.1016/bs.acc.2022.03.002, (31-73), . Kim K and Jang W (2021) NXNL1 negatively regulates osteoblast differentiation via GDF15‐induced PP2A Cα dependent manner in MC3T3‐E1 cells, BioFactors, 10.1002/biof.1817, 48:1, (239-248), Online publication date: 1-Jan-2022. Negishi K, Hoshide S, Shimpo M, Kanegae H and Kario K (2021) Growth Differentiation Factor‐15 Predicts Death and Stroke Event in Outpatients With Cardiovascular Risk Factors: The J‐HOP Study, Journal of the American Heart Association, 10:24, Online publication date: 21-Dec-2021. Stemmler A, Symmank J, Steinmetz J, von Brandenstein K, Hennig C and Jacobs C (2021) GDF15 Supports the Inflammatory Response of PdL Fibroblasts Stimulated by P. gingivalis LPS and Concurrent Compression, International Journal of Molecular Sciences, 10.3390/ijms222413608, 22:24, (13608) Sun T, Peng R, Sun X and Li Y (2021) Associations between Sex Hormones and Circulating Growth Differentiation Factor-15 in Male Patients with Major Depressive Disorder, Brain Sciences, 10.3390/brainsci11121612, 11:12, (1612) Verdonschot J, Ferreira J, Pellicori P, Brunner-La Rocca H, Clark A, Cosmi F, Cuthbert J, Girerd N, Mariottoni B, Petutschnigg J, Rossignol P, Cleland J, Zannad F and Heymans S (2021) Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial, Cardiovascular Diabetology, 10.1186/s12933-021-01357-9, 20:1, Online publication date: 1-Dec-2021. Zhang Y, Wang Z, Zhang Y and Pei J Expression of Phosphatase and Tensin Homolog Deleted on Chromosome Ten on the Development of Cisplatin Resistance in Breast Cancer by TGF- β 1 Signal Pathway , Journal of Biomaterials and Tissue Engineering, 10.1166/jbt.2021.2788, 11:10, (1900-1907) Huang H, Chen Z, Li Y, Gong K, Xiao L, Fu H, Yang J, Wang X, Meng Q and Zhang F (2021) GDF-15 Suppresses Atherosclerosis by Inhibiting oxLDL-Induced Lipid Accumulation and Inflammation in Macrophages, Evidence-Based Complementary and Alternative Medicine, 10.1155/2021/6497568, 2021, (1-13), Online publication date: 7-Sep-2021. di Candia A, de Avila D, Moreira G, Villacorta H and Maisel A (2021) Growth differentiation factor-15, a novel systemic biomarker of oxidative stress, inflammation, and cellular aging: Potential role in cardiovascular diseases, American Heart Journal Plus: Cardiology Research and Practice, 10.1016/j.ahjo.2021.100046, 9, (100046), Online publication date: 1-Sep-2021. Rochette L, Dogon G, Zeller M, Cottin Y and Vergely C (2021) GDF15 and Cardiac Cells: Current Concepts and New Insights, International Journal of Molecular Sciences, 10.3390/ijms22168889, 22:16, (8889) Uysal C, Arslan D, Buyukinan M, Gederet Y, Vatansev H and Ozcelik H (2019) Growth Differentiation Factor-15 Level and Tissue Doppler Echocardiography as a Tool in Identification of Cardiac Effects in the Children with Type 1 Diabetes Mellitus, Experimental and Clinical Endocrinology & Diabetes, 10.1055/a-0983-1673, 129:08, (574-580), Online publication date: 1-Aug-2021. Aguilar-Recarte D, Barroso E, Gumà A, Pizarro-Delgado J, Peña L, Ruart M, Palomer X, Wahli W and Vázquez-Carrera M (2021) GDF15 mediates the metabolic effects of PPARβ/δ by activating AMPK, Cell Reports, 10.1016/j.celrep.2021.109501, 36:6, (109501), Online publication date: 1-Aug-2021. Negishi K, Hoshide S, Shimpo M and Kario K (2021) Growth Differentiation Factor 15 Predicts Cancer Death in Patients With Cardiovascular Risk Factors: The J-HOP Study, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2021.660317, 8 Kato T, Nakajima T, Fukuda T, Shibasaki I, Hasegawa T, Ogata K, Ogawa H, Hirota S, Ohashi H, Saito S, Takei Y, Tezuka M, Seki M, Kuwata T, Sakuma M, Abe S, Toyoda S, Inoue T and Fukuda H (2021) Preoperative Serum GDF-15, Endothelin-1 Levels, and Intraoperative Factors as Short-Term Operative Risks for Patients Undergoing Cardiovascular Surgery, Journal of Clinical Medicine, 10.3390/jcm10091960, 10:9, (1960) Deshmukh A, Ghannam M, Liang J, Saeed M, Cunnane R, Ghanbari H, Latchamsetty R, Crawford T, Batul S, Chung E, Bogun F, Jongnarangsin K, Pelosi F, Chugh A, Morady F, Oral E and Oral H (2021) Effect of metformin on outcomes of catheter ablation for atrial fibrillation, Journal of Cardiovascular Electrophysiology, 10.1111/jce.14954, 32:5, (1232-1239), Online publication date: 1-May-2021. Zorn S, Rayan D, Brown S and Bergom C (2021) Radiation-Induced Cardiotoxicity, Advances in Oncology, 10.1016/j.yao.2021.02.001, 1, (1-13), Online publication date: 1-May-2021. Cheng J, Gu W, Lan T, Deng J, Ni Z, Zhang Z, Hu Y, Sun X, Yang Y and Xu Q (2020) Single-cell RNA sequencing reveals cell type- and artery type-specific vascular remodelling in male spontaneously hypertensive rats, Cardiovascular Research, 10.1093/cvr/cvaa164, 117:4, (1202-1216), Online publication date: 21-Mar-2021. Ye D, Liu B, He Z, Huang L, Qian Y, Shao K, Wen C and Mao Y (2021) Assessing the Associations of Growth Differentiation Factor 15 with Rheumatic Diseases Using Genetic Data, Clinical Epidemiology, 10.2147/CLEP.S305024, Volume 13, (245-252) Iwata Y, Inagaki S, Morozumi W, Nakamura S, Hara H and Shimazawa M (2021) Treatment with GDF15, a TGFβ superfamily protein, induces protective effect on retinal ganglion cells, Experimental Eye Research, 10.1016/j.exer.2020.108338, 202, (108338), Online publication date: 1-Jan-2021. Yamaguchi H, Nishiyama M, Tokumoto S, Ishida Y, Tomioka K, Aoki K, Seino Y, Toyoshima D, Takeda H, Kurosawa H, Sakuma H, Tada H, Nozu K, Maruyama A, Tanaka R, Iijima K and Nagase H (2021) Elevated cytokine, chemokine, and growth and differentiation factor-15 levels in hemorrhagic shock and encephalopathy syndrome: A retrospective observational study, Cytokine, 10.1016/j.cyto.2020.155324, 137, (155324), Online publication date: 1-Jan-2021. Rochette L, Zeller M, Cottin Y and Vergely C (2020) Insights Into Mechanisms of GDF15 and Receptor GFRAL: Therapeutic Targets, Trends in Endocrinology & Metabolism, 10.1016/j.tem.2020.10.004, 31:12, (939-951), Online publication date: 1-Dec-2020. Hansen E, Hindberg K, Latysheva N, Aukrust P, Ueland T, Hansen J, Brækkan S and Morelli V (2020) Plasma levels of growth differentiation factor 15 are associated with future risk of venous thromboembolism, Blood, 10.1182/blood.2019004572, 136:16, (1863-1870), Online publication date: 15-Oct-2020. Spanopoulou A and Gkretsi V (2020) Growth differentiation factor 15 (GDF15) in cancer cell metastasis: from the cells to the patients, Clinical & Experimental Metastasis, 10.1007/s10585-020-10041-3, 37:4, (451-464), Online publication date: 1-Aug-2020. Wesseling M, Poel J and Jager S (2020) Growth differentiation factor 15 in adverse cardiac remodelling: from biomarker to causal player, ESC Heart Failure, 10.1002/ehf2.12728, 7:4, (1488-1501), Online publication date: 1-Aug-2020. Vermeulen B, Schutte A, Gafane-Matemane L and Kruger R (2020) Growth differentiating factor-15 and its association with traditional cardiovascular risk factors: The African-PREDICT study, Nutrition, Metabolism and Cardiovascular Diseases, 10.1016/j.numecd.2020.03.001, 30:6, (925-931), Online publication date: 1-Jun-2020. Rullman E, Melin M, Mandić M, Gonon A, Fernandez-Gonzalo R and Gustafsson T (2019) Circulatory factors associated with function and prognosis in patients with severe heart failure, Clinical Research in Cardiology, 10.1007/s00392-019-01554-3, 109:6, (655-672), Online publication date: 1-Jun-2020. Dogdu O (2020) Assessment of Growth Differentiation Factor 15 Levels on Coronary Flow in Patients with STEMI Undergoing Primary PCI, Diseases, 10.3390/diseases8020016, 8:2, (16) Wischhusen J, Melero I and Fridman W (2020) Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint, Frontiers in Immunology, 10.3389/fimmu.2020.00951, 11 Chen J, Dai W, Zhu C, Liu H, L
Referência(s)